Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • US inflation eased slightly in July on lower petrol prices
    • Trump refuses to answer questions in New York state probe
    • FBI raid adds to Donald Trump’s litany of legal woes
    • ‘We’re going to fight until the end’: FBI Mar-a-Lago raid fires up Trump’s base
    • ‘She is the leader Taiwan needed’: softly spoken president draws China’s rage
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Carlyle boss quit after failed request for $300mn pay package
      • Robinhood suffers harshest hangover after pandemic stock trading boom
      • SFO secures conviction in £100mn litigation finance fund fraud
      • Credit Suisse steps up legal claim against SoftBank in $440mn dispute
      • Layoffs during a jobs boom: the paradox of the US labour market
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
      Most Read
      • Elon Musk sells $7bn of Tesla stock ahead of court fight with Twitter
      • Nasdaq rallies more than 20% from recent lows after US inflation eases
      • SoftBank set to post $34bn gain after handing over Alibaba shares
      • Live news updates from August 10: US inflation eases slightly, Trump pleads Fifth Amendment in New York probe
      • Norway’s unexpected energy crisis
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • The unexpected triumph of Joe Biden
      • Germany is now the fulcrum for Vladimir Putin’s pressure
      • Mortgage wake-up call for middle classes
      • Tory terror spurs new war with the state
      • Are you heading for a financial car crash?
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Can a city be redesigned for the new world of work?
      • Brompton’s Will Butler-Adams: ‘People have no idea what goes into a product. That’s not a good thing’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • A €1 dream scheme sparks a wider homebuying trend in Sicily
      • How I fell for the boxer, again
      • Britain’s housing crisis — no longer a nation of homeowners?
      • Wheels in the wild: a bikepacking trek in Kyrgyzstan
      • Nope, review — audaciously weird spectacle is Jordan Peele’s most supersized film yet
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Your guide to a disrupted world

    Start a 4-week trial

    Hannah Kuchler

    Global Pharmaceuticals Correspondent
    Hannah Kuchler reports on the pharmaceutical industry and the Covid-19 pandemic. She previously covered US pharma and biotech in New York and the technology industry in Silicon Valley.
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)
    Email Hannah Kuchler @hannahkuchler  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 8 August, 2022
      Covid-19 vaccines
      BioNTech and Pfizer to begin vaccine clinical trial for new Covid variants

      German biotech aims for ‘prolonged and broad protection’ as sales and earnings miss expectations

    • Saturday, 30 July, 2022
      AstraZeneca PLC
      AstraZeneca to double number of countries where US biotech arm sells rare disease drugs

      Anglo-Swedish pharmaceutical group wants to capitalise on its $39bn acquisition of Alexion

    • Friday, 29 July, 2022
      AstraZeneca PLC
      AstraZeneca raises forecasts after strong Covid and cancer drug sales

      Chief executive says revenue rise will allow drugmaker to boost investment in R&D

    • Wednesday, 27 July, 2022
      GSK PLC
      GSK raises profit guidance after strong sales of shingles vaccine

      Quarterly figures beat expectations as pharma group strengthens pipeline of new drugs

    • Thursday, 21 July, 2022
      Joe Biden
      Joe Biden has contracted Covid, White House says

      US president has ‘very mild symptoms’ and is taking Pfizer antiviral pill

    • Wednesday, 20 July, 2022
      Biotech
      Cambridge biotech Abcam to abandon London listing for Nasdaq

      Further blow to UK stock market comes despite government’s efforts to promote life sciences

    • Saturday, 16 July, 2022
      GSK PLC
      GSK split will help deal with ‘perennial underperformance’, says chief

      Emma Walmsley believes listing of consumer health business will strengthen pharma division

    • Thursday, 14 July, 2022
      FT Magazine
      A new ‘miracle’ weight-loss drug really works — raising huge questions

      Novo Nordisk’s Wegovy uses a hormone to regulate hunger. It’s wildly effective, but is it misguided?

    • Thursday, 14 July, 2022
      Health
      UK lags behind EU in authorising new medicines after Brexit

      Experts attribute shortfall to small size of British market now it is regulated separately and complexity of dealing with NHS

    • Wednesday, 13 July, 2022
      Pfizer Inc
      Why Pfizer’s ‘living with Covid’ pill is not a miracle drug

      Antiviral treatment Paxlovid is being widely prescribed despite questions about its effectiveness

    • Sunday, 10 July, 2022
      Covid-19 vaccines
      More than 1bn Covid vaccine jabs wasted in pandemic, data analysis suggests

      Shots unused due to factors including hesitancy, improper storage and donations delivered close to expiry dates

    • Thursday, 7 July, 2022
      Pharmaceuticals sector
      Merck in talks over $40bn deal for cancer biotech SeaGen

      US group attracted by approved drugs as it prepares to lose patent protection of Keytruda

    • Wednesday, 6 July, 2022
      GSK PLC
      GSK investor support for spin-off vindicates rejection of Unilever bid, says chief

      Vote to separate consumer healthcare paves way for London’s largest stock market listing in a decade

    • Wednesday, 6 July, 2022
      FT Financial Literacy and Inclusion Campaign
      Employers urged to help workers navigate stresses of cost of living crisis

      Mounting money worries spark calls for companies to support workers’ financial wellbeing

    • Tuesday, 5 July, 2022
      CureVac GmbH
      CureVac sues BioNTech over mRNA patents

      Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements

    • Friday, 1 July, 2022
      Covid-19 vaccines
      Oxford BioMedica extends Covid vaccine deal with AstraZeneca

      New three-year contract in place if UK drugmaker continues to manufacture the jab

    • Wednesday, 29 June, 2022
      Q&ACoronavirus pandemic
      How worried should we be about new Covid variants?

      FT science editor Clive Cookson and global pharma correspondent Hannah Kuchler answered your questions about rising Omicron infections and vaccine efficiency

    • Monday, 27 June, 2022
      Croda International PLC
      US government to invest up to $75mn in new Croda factory

      Washington seeks to expand domestic production of crucial component of mRNA vaccines

    • Saturday, 25 June, 2022
      Covid-19 vaccines
      BioNTech/Pfizer say Omicron-targeting boosters elicit strong immune response

      New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain

    • Friday, 24 June, 2022
      Covid-19 vaccines
      Sanofi-GSK Covid vaccine found effective against Omicron

      Pharma companies are hoping to catch up with rivals as they report promising trial results for jab

    • Thursday, 23 June, 2022
      Coronavirus treatment
      UK prepares to include over-50s in autumn Covid booster campaign

      Javid says he asked officials to revise previous plans that would exclude under-65s

    • Wednesday, 22 June, 2022
      Moderna
      Moderna calls for approval of two-strain Covid vaccine booster

      US biotech group says shot targeting both first strain and Omicron could help avert ‘large rise’ in cases

    • Wednesday, 22 June, 2022
      Covid-19 vaccines
      UK signs £1bn deal with Moderna for new vaccine centre

      Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech

    • Saturday, 18 June, 2022
      Covid-19 vaccines
      BioNTech chief calls for speedy ruling on Covid vaccines that target latest strains

      ‘Time is ticking’ as studies suggest original Omicron jabs may not offer strong protection against sub-variants

    • Tuesday, 14 June, 2022
      The Big Read
      BioNTech’s second act: can it transform the fight against cancer?

      The German company is ploughing Covid vaccine profits into oncology but its technology is still largely unproven

    Previous page You are on page 1 Next page

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT LiveGlobal Pharma and Biotech SummitDriving Investment and Innovation in Life Sciences
    Monday, 7th NovemberRoyal Lancaster Hotel, London
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In